Hulskof schreef op 1 juli 2021 13:26:
Adi: "Over the next several months, we have a number of value-creating events on AFM13, AFM24, where we expect to initiate several clinical studies, and AFM28, and are allocating capital across our portfolio to develop multiple opportunities for shareholder value creation.”
Vrij vertaald: We zullen binnenkort weer met de pet langs moeten.